Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer - Concepedia

Concepedia

Publication | Closed Access

Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

754

Citations

27

References

2007

Year

Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey A. Douglas, Robert A. Burger, Deborah K. Armstrong, Robert M. Wenham,

Journal of Clinical Oncology

Abstract

Bevacizumab has single-agent activity in patients with platinum-resistant EOC or PSC. A higher than expected incidence of GIP was noted in these heavily pretreated patients.

References

	Year	Citations

Page 1